Última Hora: "Lisboa vai ser a ?escolha número um? para investir em imobiliário na Europa - ECO Economia Online" Sun, 18 Nov 2018 14:03:45 GMT    "Fiscais da Carris vão começar a passar multas de estacionamento - Jornal Económico" Sun, 18 Nov 2018 09:29:00 GMT    "«Operadoras preparam aumento dos preços» - Negócios - A Bola" Mon, 19 Nov 2018 07:31:37 GMT    "Apagão de rede bancária em Moçambique deve-se a falta de pagamento pelo 'software' - fornecedor - Diário de Notícias - Lisboa" Sun, 18 Nov 2018 21:26:29 GMT    "SIMAB vai instalar cidade comercial na China - Jornal Económico" Sun, 18 Nov 2018 17:13:00 GMT    "Banco CTT ?não se tem ressentido? de situação dos CTT - Jornal de Negócios - Portugal" Sun, 18 Nov 2018 12:00:41 GMT    "Gasóleo ficou mais caro 11 cêntimos num ano - Sul Informacao" Sun, 18 Nov 2018 12:15:00 GMT    "Trotinetes da Lime vão ter concorrência. VOI fecha financiamento para abrir em Portugal - Jornal Económico" Mon, 19 Nov 2018 00:01:00 GMT   "" Mon, 19 Nov 2018 07:42:37 GMT    "Número de empresas a fechar duplicou - Dinheiro Vivo" Mon, 19 Nov 2018 07:17:13 GMT      Para mais notícias, clique aqui.

Área de Acesso
       
       
Lembrar Sempre 
(Login BolsaPT & Canal Forex)

Procure análises técnicas no nosso fórum aqui: Análises Técnicas
Nota: Os dados após 2018-11-13 são ainda temporários e poderão por isso ter o valor de Abertura errado até nova actualização...
Mudar para Gráfico Estático de SCHERING PLOUGH C

Queda de
--59.00 (+0.83%) SCHERING PLOUGH C - [Ticker: SGP]Gráfico SCHERING PLOUGH C  Notícias SCHERING PLOUGH C  Download de Históricos Metastock SCHERING PLOUGH C e Outros  Análise Técnica SCHERING PLOUGH C  
Última Trade290,000Range 52 Semanas[0,000 - 0,000]
Hora da Última Trade2018-11-13 - 00:00:00Price-Target 1 Ano0,000
Variação--59.00 (+0.83%)Capitalização Bolsista0
Bid / AskN/AEPS0,00
Abertura290,200PER0,00%
Máximo290,200Pagamento Dividendo
Mínimo290,000Data Ex-Dividendo
Fecho Anterior349,000Yield
Volume160Volume Médio (3m)0
Nota: Os dados podem apresentar atraso de alguns minutos.

 Notícias sobre SCHERING PLOUGH C [SGP]:   (ordenadas por relevância)

BioTelemetry, Inc. Elects Stephan Rietiker to its Board of Directors
Nasdaq
Prior to becoming CEO of LifeWatch AG in 2014, Dr. Rietiker held executive roles at Roche, Boehringer Mannheim, Schering Plough, Covance and as CEO of Centerpulse (formerly Sulzer Medica). Additionally, he has been an investor, executive and Board ...

e mais »

Interferon Biosimilar Market Global Insights and Trends 2018 to 2025
thestocknewsnow.com
Rhein Minapharm Biogenetics. PROBIOMED. 3sbio. Amgen. Bayer. Schering Plough. Merck. On the basis of product, this report displays the production, revenue, price, and market share and growth rate of each type, primarily split into: Hepatitis C ...

e mais »

Snelson Named AASV New Executive Director
Pork Magazine
For the first time in 25 years, the American Association of Swine Veterinarians (AASV) will have a new Executive Director, Dr. Harry Snelson. Snelson, who is the current AASV Director of Communications, has had a long association with the organization ...


Dacca Times

Anti-Viral Drugs Market 2018-2023 by Region, Manufacturer ...
Dacca Times
Top Key Players Segment Analysis: Schering-Plough, Gilead, AstraZeneca, Cipla, Roche, Merck & Co, Bristol-Myers-Squibb, GlaxoSmithKline, Johnson & Johnson, Abbott. Anti-Viral Drugs Market Report Provides Comprehensive Analysis Of: Key Anti-Viral ...

e mais »

National Hog Farmer

Snelson named AASV executive director
National Hog Farmer
... Medicine and then spent 10 years as the swine veterinarian for Carroll's Foods in Warsaw, N.C. In 2000, he accepted a position as a swine technical services veterinarian with Schering-Plough Animal Health before leaving in 2003 to become the ...


Global Interferon Biosimilar Market Revenue, Key Factors Analysis ...
Digital Journal
Biosidus. Zydus Cadila. Nanogen. Amega Biotech. Rhein Minapharm Biogenetics. PROBIOMED. 3sbio. Amgen. Bayer. Schering Plough. Merck. Market Segment by Product Type. Long-lasting Type. Ordinary Type. Market Segment by Application. Hepatitis C.

e mais »

Global Interferon Biosimilar Market 2018- 2025|Details Analysis By ...
MENAFN.COM
(MENAFN Editorial) iCrowdNewswire - Oct 17, 2018. In this report, the global Interferon Biosimilar market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.


Global Interferon Biosimilar Market 2018-2025 Roche, Biosidus ...
chemicalindustry24.com
Global Market Study Interferon Biosimilar Market Provide Forecast Report 2018 ? 2025 presents an detailed analysis of the Interferon Biosimilar which researched industry situations, market Size, growth and demands, Interferon Biosimilar market outlook, ...

e mais »

LANews By Abhishek Budholiya (press release) (blog)

Anti-Viral Drugs Market to Witness Robust Expansion Throughout ...
LANews By Abhishek Budholiya (press release) (blog)
Based on product type, the global anti-viral drugs market is segmented into the following: Hepatitis-C antivirals, HIV antivirals, Herpes antivirals, Hepatitis-B antivirals, Influenza antivirals, Others (Pneumonia, Flu, etc.) ... global anti-viral ...


EyePoint Pharmaceuticals, Inc.
StreetInsider.com
the annual meeting and the reasons for conducting such business at the annual meeting, (b) the name, age and business and residential address, as they appear on the corporation's records, of the stockholder proposing such business, (c) the class and ...

e mais »

Interferon Biosimilar Market Growth Rate at CAGR(%) and Regional ...
Industry Today (press release)
Zydus Cadila. Nanogen. Amega Biotech. Rhein Minapharm Biogenetics. PROBIOMED. 3sbio. Amgen. Bayer. Schering Plough. Merck. Market Size Split by Type. Long-lasting Type. Ordinary Type. Market Size Split by Application. Hepatitis C. Hepatitis B.

e mais »

LANews By Abhishek Budholiya (press release) (blog)

Anti-Viral Drugs Market Is Expected To Generate Huge Profits by ...
LANews By Abhishek Budholiya (press release) (blog)
Based on product type, the global anti-viral drugs market is segmented into the following:Hepatitis-C antivirals,HIV antivirals,Herpes antivirals,Hepatitis-B antivirals,Influenza antivirals,Others (Pneumonia, Flu, etc.). ... Some of the key players in ...


Florida Daily Chronicle

Global Anti-Viral Drugs Market Demand 2018-2025: Roche, Abbott ...
Florida Daily Chronicle
The report demonstrates the outstanding market players such as Roche, Abbott, AstraZeneca, GlaxoSmithKline, Gilead, Johnson & Johnson, Cipla, Merck & Co, Bristol-Myers-Squibb, Schering-Plough of the global Anti-Viral Drugs market. It presents wide ...

e mais »

Redfield Herald (press release) (blog)

Anti-Viral Drugs Market Capital to Gain Maximum Attention ...
Redfield Herald (press release) (blog)
The report includes the forecasts, Analysis and discussion of important industry trends, market size, market share estimates and profiles of the leading industry Players: ,Schering-Plough ,Gilead ,AstraZeneca ,Cipla ,Rocheerck & Co ,Bristol-Myers ...


Reuters

Keytruda sales power Merck to quarterly beat
Reuters
(Reuters) - Drugmaker Merck & Co (MRK.N) reported better-than-expected first-quarter earnings on Tuesday, helped by a more than 150 percent rise in sales of blockbuster cancer drug Keytruda.

Para mais notícias sobre SCHERING PLOUGH C clique aqui:
Notícias de SCHERING PLOUGH C 


Largura do Site:

 Imagem de Fundo:

Copyright@1998-2018 - BolsaPT.com, todos os direitos reservados.
Fórum de Bolsa Cotações de Bolsa Notícias de Bolsa Chat de Bolsa Disclaimer Recursos para Webmasters